赛诺菲与HμREL合作进行临床前技术研究

liuzff

制药巨头赛诺菲的美国分公司宣布与HμREL公司合作进行一项关于人工组织和细胞生物学技术的研究，这一研究旨在取代药物研发过程中实验动物的作用。根据协议，赛诺菲美国将资助HμREL公司一系列相关研究，如HμRELhumanTM 3D 肝组织共培养物。这种人工组织可被用于广泛的药物研究和细胞毒性、药物代谢研究。赛诺菲美国表示，这次合作是公司开发新型生命科学技术的一次契机。合作双方计划将于晚些时候公布合作细节。（生物谷Bioon.com）

详细英文报道：

Sanofi's U.S. arm has tapped HμREL to gain access to the biotech's artificial tissues and cell-based technologies aimed at replacing animals in preclinical drug development.

HμREL is pioneering "organ on a chip" in vitro systems for drug development. The North Brunswick, NJ-based biotech's 3-dimensional tissue cultures simulate and predict the in vivo function of the liver and other organs.

Under the R&D collaboration agreement, Sanofi US will fund a range of studies that will evaluate HμREL's technologies, starting with HμREL's HμRELhumanTM 3D liver tissue coculture. The 3-D tissue is designed for use in various experimental requirements conducted in the preclinical phase of drug discovery and development, such as studies of toxicology, drug metabolism and pharmacokinetics.

"Our partnership with HμREL is an opportunity to leverage an innovative new life sciences technology to accelerate drug development and impact the lives of patients," said Marc Bonnefoi, head of Sanofi's North America R&D Hub, in a statement.

Different aspects of the collaboration will be carried out in HμREL's New Jersey laboratories as well as at various Sanofi R&D locations in both the United States and Europe, according to a HμREL press release.

HμREL and Sanofi ($SNY) say they plan to publish the results of their R&D partnership.